Navigation Links
Rigel Announces Presentations at Two Investor Conferences
Date:10/28/2009

SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul R. Rodriguez, executive vice president and chief operating officer of Rigel, will present at two separate investor conferences in November. Details of each conference are as follows:

    Oppenheimer 20th Annual Healthcare Conference
    Waldorf Astoria, New York City, NY
    November 3, 2:10 p.m. EST
    Speaker: Raul R. Rodriguez

    Credit Suisse 18th Annual Healthcare Conference
    Arizona Biltmore Hotel, Phoenix, AZ
    November 11, 2:00 p.m. MST
    Speaker: James M. Gower

Both presentations will be webcast. To access the live webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

    Contact: Raul R. Rodriguez
    Phone: 650-624-1302
    Email: invrel@rigel
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
2. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
3. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
4. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
5. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
6. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
7. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
8. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
9. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
10. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
11. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 A case report and ... SynCardia temporary Total Artificial Heart into a patient with ... were reversed, along with other abnormalities. ... the SynCardia Total Artificial Heart to treat a patient ... and video in the Journal of Visualized Experiments show ...
(Date:9/23/2014)... Sept. 23, 2014  Savant HWP, Inc., a ... initiation of human safety testing of 18-MC, an ... single dose of 18-MC, administered as part of ... Savant,s South American partner, was well tolerated by ... plans to develop 18-MC as a treatment for ...
(Date:9/23/2014)... BOTHELL, Wash. , Sept. 23, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced two new additions to its Scientific Advisory Board.  ... and Anthony Davies , PhD. Dr. ...
Breaking Medicine Technology:1st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 2Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7
... -- Weikang Bio-technology Group, Inc. (the "Company," "Weikang" or ... all of its management departments into the building it ... Chengde Street in the Daowai District of Harbin, the ... of the building. Mr. Yin Wang, the ...
... Dec. 27, 2011  PharmacoFore, Inc., a privately held biopharmaceutical ... equity financing from Founders Fund and the addition ... Board of Directors.   PharmacoFore uses innovative ... treating a variety of conditions related to the ...
Cached Medicine Technology:Weikang Bio-technology Group, Inc. Completes HQ Relocation After Purchasing Building for $14 Million and Answers Questions About its Third Quarter Financials 2Weikang Bio-technology Group, Inc. Completes HQ Relocation After Purchasing Building for $14 Million and Answers Questions About its Third Quarter Financials 3PharmacoFore, Inc. Secures $10 Million in Equity Financing From Founders Fund 2
(Date:9/23/2014)... What: Rutgers Presbyterian Church, a ... that embodies the inclusion and diversity of New ... the Ecological Crisis, a public lecture led by ... of Old Testament at Louisville Presbyterian Seminary. Tull ... lends insight into current ecological problems, including energy ...
(Date:9/23/2014)... teenagers could grow up to earn up to 18 ... says Petter Lundborg of Lund University, Paul Nystedt of ... Lund University, all in Sweden. The team compared extensive ... States, and the results are published in Springer,s journal ... data of 145,193 Swedish-born brothers who enlisted in the ...
(Date:9/23/2014)... 2014 Trevera provides multiple lines ... are Oracle Managed Services , Oracle Solutions ... versions of Oracle E-Business Databases and Applications, ... Trevera has announced a significant enhancement to its ... with their software technology management, project management, governance, ...
(Date:9/23/2014)... Greensboro, NC (PRWEB) September 23, 2014 ... (UNCG), a national research university located In the ... has joined UNCG as co-director of the Center ... in bioanalytical chemistry, comes to UNCG after nearly ... Pacific Northwest National Laboratory, Biological Sciences Division. ...
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 (HealthDay ... for a hemorrhagic stroke -- which causes bleeding in the ... survive than people who weren,t taking the drugs, according to ... known as statins were also 2.5 times more likely to ... reports. When it comes to the best treatment for ...
Breaking Medicine News(10 mins):Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:Note to young men: Fat doesn't pay 2Health News:Trevera, Inc adds Management Support to Services 2Health News:Trevera, Inc adds Management Support to Services 3Health News:Former Department of Energy Scientist Joins UNCG as Co-director of Biomedical Research Center 2Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 2Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 3
... why some of the bacteria that cause stomach ulcers ... cancer than others; it turns out these bacteria can ... the immune system. , Helicobacter pylori is a bacterial ... inflammation, ulcers, and potentially even stomach cancer. However, only ...
... LOUIS, Aug. 22 CMS, Inc., an Elekta ... workflow management,solutions, has received FDA 510(k) clearance for ... CMS to immediately,begin distributing Atlas-Based Autosegmentation for clinical ... amount of time spent creating and editing,patient contours, ...
... to launch the most sophisticated mission ever to investigate ... shape of our planet the geoid - with ... steady-state Ocean Circulation Explorer (GOCE) will be placed onto ... Rockot vehicle launched from the Plesetsk Cosmodrome in Northern ...
... But the agency says patients can still take ... News) -- U.S. drug regulators said Thursday that ... might be linked to cancer. , The U.S. ... health-care professionals that the agency was investigating a ...
... to its superior service, ... and innovative technology, FORT WORTH, Texas, Aug. 22 ... services to the retail pharmacy,industry, today announced that it ... editing and reporting services business,partner. eRx Network,s suite of ...
... halide compounds, American Elements announced today it has increased the capacity ... , ... Los Angeles, CA (PRWEB) August 22, 2008 -- ... today it has increased the capacity for U.S. based manufacturing of ...
Cached Medicine News:Health News:CMS, Inc., an Elekta Company, Receives FDA 510(k) Clearance for Atlas-Based Autosegmentation Software 2Health News:GOCE Earth explorer satellite to look at the Earth's surface and core 2Health News:FDA Investigates Possible Vytorin-Cancer Link 2Health News:FDA Investigates Possible Vytorin-Cancer Link 3Health News:Kmart Pharmacy Awards Its Transaction Processing Business to eRx Network 2
... Eliminate aerosol contamination, which ... in PCR. Hydrophobic, nonwicking ... air can pass through ... in contrast to tips ...
... Aerosol barrier tips eliminate false ... Scientifically designed and tested, Promega Barrier ... working with amplified nucleic acids (PCR(a)), ... samples, forensic and serological specimens. , ...
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
... Finntip Filters are ideal ... methods, or for any work ... They are designed for pipetting ... samples, and other. For applications ...
Medicine Products: